Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
J&J’s Janssen Pharmaceutical Companies submitted a Marketing Authorization Application to the EMA for apalutamide for non-metastatic castration-resistant prostate cancer.
Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the appointment of Lisa van Capelle as Chief Human Resources Officer (CHRO).
The American College of Rheumatology published a new white paper, “The Science Behind Biosimilars – Entering a New Era of Biologic Therapy,” providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, competition and drug pricing.
Digital marketing agency closerlook inc. appointed Steve Tulk to the role of Chief Technology Officer.
Ashfield, part of leading international healthcare services provider UDG Healthcare, announced the appointment of Doug Burcin as president of Ashfield Healthcare Communications.
Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study OPTIMISMM achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for the pomalidomide arm versus the comparator arm.
Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.
Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.
